The clinical utility of liposomal doxorubicin in recurrent ovarian cancer

Citation
Sm. Campos et al., The clinical utility of liposomal doxorubicin in recurrent ovarian cancer, GYNECOL ONC, 81(2), 2001, pp. 206-212
Citations number
31
Categorie Soggetti
Reproductive Medicine
Journal title
GYNECOLOGIC ONCOLOGY
ISSN journal
00908258 → ACNP
Volume
81
Issue
2
Year of publication
2001
Pages
206 - 212
Database
ISI
SICI code
0090-8258(200105)81:2<206:TCUOLD>2.0.ZU;2-L
Abstract
Objectives. The aim of this study was to determine the efficacy and toxicit y of single agent off-protocol, liposomal doxorubicin (Doxil Alza), in cons ecutive patients with recurrent ovarian cancer and to investigate the influ ence of HER-2/neu expression on response to liposomal doxorubicin, Patients and methods, Retrospective analysis of 72 consecutive patients tre ated, typically with liposomal doxorubicin 40 mg/m(2) q28 days between Janu ary 1997 and December 1998. Results. Twenty-nine patients (40%) had platinum- and taxane-resistant tumo rs. Nineteen patients (27%) responded with clinical or radiological evidenc e of response with reduction in CA-125 of > 50%. One complete response (CR) and 7 partial responses (PRs) occurred in platinum- and taxane-resistant p atients (radiological response (RR) 29%) and 8 PRs occurred in patients wit h visceral metastases (RR 28%), Time to progression was 5.3 (2.1-12.1) mont hs. Only 7 dose delays (3%) and 20 dose reductions (8%) were necessary in 2 65 cycles of treatment. Hematological toxicity was generally mild with grad e (Gr) greater than or equal to III neutropenia in 1 (2%), Gr greater than or equal to III thrombocytopenia in 1 (1%), and Or greater than or equal to III anemia in 8 patients (11%). One patient (1%) was admitted with fever a nd neutropenia. Other toxicity was minimal with Gr greater than or equal to III mucositis occurring in 3 patients (4%), Gr greater than or equal to II I cutaneous toxicity was seen in 6 patients (8%). Three patients (4%) had a > 10% fall in ejection fraction but there was no unequivocal clinical hear t failure, Conclusions. The data suggest that liposomal doxorubicin is an a ctive drug in both taxane- and platinum-sensitive and resistant recurrent o varian cancer. Liposomal doxorubicin is associated with tolerable toxicity and is particularly well tolerated in patients with multiple prior lines of treatment. (C) 2001 Academic Press.